nature portfolio

Corresponding outhor(s).	NCOMMS-23-24855
Corresponding author(s):	05/00/0000
Last updated by author(s):	05/06/2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u> .		
Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.		
Statistics		
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.		
n/a Confirmed		
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement		
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly		
The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.		
A description of all covariates tested		
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons		
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)		
For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.		
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings		
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes		
Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated		
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.		
Software and code		
Policy information about <u>availability of computer code</u>		
Data collection Illumina MiniSeq instrument		
Data analysis GraphPad Prism(8.1.2), BE-and PE-analyzer (http://www.rgenome.net/be-analyzer/ GH Hwang et al, BMC Bioinf, 201		
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.		
Nata .		

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The data are available upon reasonable requests from the corresponding author.

Research inv	olving human participants, their data, or biological material
	bout studies with

Data exclusions

Non-participation

Randomization

Study description Research sample	
Research sample	
Sampling strategy	
Data collection	
Timing and spatial scale	
Data exclusions	
Reproducibility	
Randomization	
Blinding	
Field conditions Location Access & import/export	
Disturbance	
e require information from authoristem or method listed is relevant all aterials & experimental all and in the study Antibodies	ors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. Methods Methods
√ Eukaryotic cell lines	└ → └─
Eukaryotic cell lines Palaeontology and arch	aeology MRI-based neuroimaging
7 -	———

Antibodies

Antibodies used	No antibody was used in this study.
Validation	

Eukaryotic cell line	es established to the second of the second o
Policy information about <u>cel</u>	Il lines and Sex and Gender in Research
Cell line source(s)	Human ESCs: purchased from WiCell (WA09), human iPSCs: SES8 and BJ-iPSC were obtained from the research groups cited in the main text.
Authentication	Two human iPSC lines were validated in the research papers cited in the main text.
Mycoplasma contamination	Human PSC cells used in this study were tested
Commonly misidentified li (See <u>ICLAC</u> register)	ines No commonly misidentified line was used in this study.
Palaeontology and	d Archaeology
Specimen provenance	
Specimen deposition	
Dating methods	
Tick this box to confirm	n that the raw and calibrated dates are available in the paper or in Supplementary Information.
Ethics oversight	
Note that full information on th	ne approval of the study protocol must also be provided in the manuscript.
Animals and other	r research organisms
	udies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in
Laboratory animals	
Wild animals	
Reporting on sex	
Field-collected samples	
Ethics oversight	
Note that full information on th	ne approval of the study protocol must also be provided in the manuscript.
Clinical data	
Policy information about <u>clir</u> All manuscripts should comply v	nical studies with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.
Clinical trial registration	
Study protocol	
Data collection	

Dual use research of concern

Policy information about <u>dual use research of concern</u>

Hazards

Outcomes

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

No Yes		
Public health		
National security		
Crops and/or livestock		
Ecosystems		
Any other significant area		
Experiments of concern		
Does the work involve any of these experiments of concern:		
No Yes		
Demonstrate how to render a vaccine ineffective		
Confer resistance to therapeutically useful antibiotics or antiviral agents		
Enhance the virulence of a pathogen or render a nonpathogen virulent		
Increase transmissibility of a pathogen		
Alter the host range of a pathogen		
Enable evasion of diagnostic/detection modalities		
Enable the weaponization of a biological agent or toxin		
Any other potentially harmful combination of experiments and agents		
Plants		
Seed stocks		
Novel plant genotypes		
Authentication		
ChIP-seq		
Data deposition		
Confirm that both raw and final processed data have been deposited in a public database such as GEO.		
Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.		
Data access links May remain private before publication.		
Files in database submission		
Genome browser session (e.g. <u>UCSC</u>)		
Methodology		
Replicates		
Sequencing depth		
Antibodies		
Peak calling parameters		
Data quality		
Software		

Flow Cytometry	
The axis scales are clearly visil All plots are contour plots wit	er and fluorochrome used (e.g. CD4-FITC). ole. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers). h outliers or pseudocolor plots. of cells or percentage (with statistics) is provided.
Methodology	
Sample preparation	
Instrument	
Software	
Cell population abundance	
Gating strategy	
Tick this box to confirm that a	figure exemplifying the gating strategy is provided in the Supplementary Information.
NAti	
Magnetic resonance in	naging
Experimental design	
Design type	
Design specifications	
Behavioral performance measure	es .
Imaging type(s)	
Field strength	
Sequence & imaging parameters	
Area of acquisition	
Diffusion MRI Used	☐ Not used
Dransaccing	
Preprocessing Preprocessing software	
Normalization	
Normalization template	
Noise and artifact removal	
Volume censoring	
Statistical modeling & infere	nce
Model type and settings	
Effect(s) tested	

ROI-based

Both

nature portfolio
reporting summa
mmar

Ē	
Ξ	
V	á
Ņ	
Ų	

Statistic type for inference		
(See Eklund et al. 2016)		
Correction		
Models & analysis		
n/a Involved in the study		
Functional and/or effective connect	tivity	
Graph analysis		
Multivariate modeling or predictive	analysis	
Functional and/or effective connectivity		
Graph analysis		

Multivariate modeling and predictive analysis